Newborn Screening for Lysosomal Storage Disorders

Abstract

Newborn screening is one of the most important public health initiatives to date, focusing on the identification of presymptomatic newborn infants with treatable conditions to reduce morbidity and mortality. The number of screening conditions continues to expand due to advances in screening technologies and the development of novel therapies. Consequently, some of the lysosomal storage disorders are now considered as candidates for newborn screening, although many challenges including identification of late-onset phenotypes remain. This review provides a critical appraisal of the current state of newborn screening for lysosomal storage disorders.

Keywords

dried blood spot - filter card - mass spectrometry

• References

• 1 Boyle CA, Bocchini Jr JA, Kelly J. Reflections on 50 years of newborn screening. Pediatrics 2014; 133 (06) 961-963
• 2 Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963; 32: 338-343
• 3 Guthrie R. Screening for “inborn errors of metabolism” in the newborn infant: a multiple test program. Birth Defects Orig Artic Ser 1968; 4: 92-96
• 4 Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968. . Available at: http://whqlibdoc.who.int/php/WHO_PHP_34.pdf
• 5 Dussault JH, Coulombe P, Laberge C, Letarte J, Guyda H, Khoury K. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975; 86 (05) 670-674
• 6 Garrick MD, Dembure P, Guthrie R. Sickle-cell anemia and other hemoglobinopathies. Procedures and strategy for screening employing spots of blood on filter paper as specimens. N Engl J Med 1973; 288 (24) 1265-1268
• 7 Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977; 45 (05) 1003-1008
• 8 Heard GS, Secor McVoy JR, Wolf B. A screening method for biotinidase deficiency in newborns. Clin Chem 1984; 30 (01) 125-127
• 9 Whitehouse CM, Dreyer RN, Yamashita M, Fenn JB. Electrospray interface for liquid chromatographs and mass spectrometers. Anal Chem 1985; 57 (03) 675-679
• 10 Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990; 13 (03) 321-324
• 11 Levy HL. Newborn screening by tandem mass spectrometry: a new era. Clin Chem 1998; 44 (12) 2401-2402
• 12 Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 1993; 39 (01) 66-71
• 13 Chace DH, Hillman SL, Millington DS, Kahler SG, Roe CR, Naylor EW. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem 1995; 41 (01) 62-68
• 14 Chace DH, Hillman SL, Millington DS, Kahler SG, Adam BW, Levy HL. Rapid diagnosis of homocystinuria and other hypermethioninemias from newborns' blood spots by tandem mass spectrometry. Clin Chem 1996; 42 (03) 349-355
• 15 Pitt JJ. Newborn screening. Clin Biochem Rev 2010; 31 (02) 57-68
• 16 Zytkovicz TH, Fitzgerald EF, Marsden D. , et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001; 47 (11) 1945-1955
• 17 Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003; 348 (23) 2304-2312
• 18 Levy HL. Newborn screening conditions: What we know, what we do not know, and how we will know it. Genet Med 2010; 12 (12) , Suppl) S213-S214
• 19 Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Genet Med 2006; 8 (Suppl. 01) 1S-252S
• 20 http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/about/index.html . Accessed April 20, 2015
• 21 Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM. Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med 2010; 12 (09) 539-543
• 22 Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004; 5 (07) 554-565
• 23 Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin Chem 2010; 56 (07) 1071-1079
• 24 Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics 2009; 123 (04) 1191-1207
• 25 Hollak CE, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 2014; 37 (04) 587-598
• 26 Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001; 308 (01/02) 195-196
• 27 Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem 2001; 47 (04) 780-781
• 28 Chamoles NA, Blanco M, Gaggioli D, Casentini C. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002; 318 (01/02) 133-137
• 29 Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases—enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002; 317 (1-2): 191-197
• 30 Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001; 47 (12) 2098-2102
• 31 Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004; 347 (01/02) 97-102
• 32 Civallero G, Michelin K, de Mari J. , et al. Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases. Clin Chim Acta 2006; 372 (01/02) 98-102
• 33 Chien YH, Chiang SC, Zhang XK. , et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008; 122 (01) e39-e45
• 34 Sista RS, Eckhardt AE, Wang T. , et al. Digital microfluidic platform for multiplexing enzyme assays: implications for lysosomal storage disease screening in newborns. Clin Chem 2011; 57 (10) 1444-1451
• 35 Sista R, Eckhardt AE, Wang T, Séllos-Moura M, Pamula VK. Rapid, single-step assay for Hunter syndrome in dried blood spots using digital microfluidics. Clin Chim Acta 2011; 412 (19-20): 1895-1897
• 36 Sista RS, Wang T, Wu N. , et al. Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform. Clin Chim Acta 2013; 424: 12-18
• 37 Gelb MH, Scott CR, Turecek F. Newborn screening for lysosomal storage diseases. Clin Chem 2015; 61 (02) 335-346
• 38 van Diggelen OP, Voznyi YV, Keulemans JL. , et al. A new fluorimetric enzyme assay for the diagnosis of Niemann-Pick A/B, with specificity of natural sphingomyelinase substrate. J Inherit Metab Dis 2005; 28 (05) 733-741
• 39 Harzer K, Rolfs A, Bauer P. , et al. Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K. Neuropediatrics 2003; 34 (06) 301-306
• 40 Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49 (11) 1797-1817
• 41 Li Y, Brockmann K, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004; 50 (03) 638-640
• 42 Li Y, Scott CR, Chamoles NA. , et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 2004; 50 (10) 1785-1796
• 43 Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem 2008; 54 (12) 2067-2070
• 44 Wolfe BJ, Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter syndrome). Anal Chem 2011; 83 (03) 1152-1156
• 45 Zhang XK, Elbin CS, Chuang WL. , et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008; 54 (10) 1725-1728
• 46 De Jesus VR, Zhang XK, Keutzer J. , et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem 2009; 55 (01) 158-164
• 47 Duffey TA, Bellamy G, Elliott S. , et al. A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Clin Chem 2010; 56 (12) 1854-1861
• 48 Mechtler TP, Metz TF, Müller HG. , et al. Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 908: 9-17
• 49 la Marca G, Casetta B, Malvagia S, Guerrini R, Zammarchi E. New strategy for the screening of lysosomal storage disorders: the use of the online trapping-and-cleanup liquid chromatography/mass spectrometry. Anal Chem 2009; 81 (15) 6113-6121
• 50 Kasper DC, Herman J, De Jesus VR, Mechtler TP, Metz TF, Shushan B. The application of multiplexed, multi-dimensional ultra-high-performance liquid chromatography/tandem mass spectrometry to the high-throughput screening of lysosomal storage disorders in newborn dried bloodspots. Rapid Commun Mass Spectrom 2010; 24 (07) 986-994
• 51 Metz TF, Mechtler TP, Orsini JJ. , et al. Simplified newborn screening protocol for lysosomal storage disorders. Clin Chem 2011; 57 (09) 1286-1294
• 52 Spáčil Z, Elliott S, Reeber SL, Gelb MH, Scott CR, Tureček F. Comparative triplex tandem mass spectrometry assays of lysosomal enzyme activities in dried blood spots using fast liquid chromatography: application to newborn screening of Pompe, Fabry, and Hurler diseases. Anal Chem 2011; 83 (12) 4822-4828
• 53 Spacil Z, Tatipaka H, Barcenas M, Scott CR, Turecek F, Gelb MH. High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin Chem 2013; 59 (03) 502-511
• 54 Meikle PJ, Grasby DJ, Dean CJ. , et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006; 88 (04) 307-314
• 55 Parkinson-Lawrence E, Fuller M, Hopwood JJ, Meikle PJ, Brooks DA. Immunochemistry of lysosomal storage disorders. Clin Chem 2006; 52 (09) 1660-1668
• 56 Umapathysivam K, Whittle AM, Ranieri E. , et al. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem 2000; 46 (09) 1318-1325
• 57 Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004; 50 (11) 1979-1985
• 58 Fuller M, Lovejoy M, Hopwood JJ, Meikle PJ. Immunoquantification of beta-glucosidase: diagnosis and prediction of severity in Gaucher disease. Clin Chem 2005; 51 (11) 2200-2202
• 59 Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem 2006; 52 (04) 643-649
• 60 Fuller M, Tucker JN, Lang DL. , et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet 2011; 48 (06) 422-425
• 61 Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab 2012; 106 (03) 281-286
• 62 Labrousse P, Chien YH, Pomponio RJ. , et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010; 99 (04) 379-383
• 63 Liao HC, Chiang CC, Niu DM. , et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry—a national newborn screening program in Taiwan. Clin Chim Acta 2014; 431: 80-86
• 64 Mechtler TP, Stary S, Metz TF. , et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012; 379 (9813): 335-341
• 65 Spada M, Pagliardini S, Yasuda M. , et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79 (01) 31-40
• 66 Wittmann J, Karg E, Turi S. , et al. Newborn screening for lysosomal storage disorders in Hungary. JIMD Rep 2012; 6: 117-125
• 67 Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013; 58 (08) 548-552
• 68 Duffner PK, Caggana M, Orsini JJ. , et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009; 40 (04) 245-252 , discussion 253–255
• 69 Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 2015; 166 (01) 172-177
• 70 Scott CR, Elliott S, Buroker N. , et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 2013; 163 (02) 498-503
• 71 Burton B, Charrow J, Angle B, Widera S, Waggoner D. A pilot newborn screening study for lysosomal storage disorders (LSD) in Illinois. Mol Genet Metab 2012; 105: S23-S24
• 72 Moyer VA, Calonge N, Teutsch SM, Botkin JR. ; United States Preventive Services Task Force Expanding newborn screening: process, policy, and priorities. Hastings Cent Rep 2008; 38 (03) 32-39
• 73 Therrell BL, Johnson A, Williams D. Status of newborn screening programs in the United States. Pediatrics 2006; 117 (5 Pt 2): S212-S252
• 74 Dees R, Kwon J. The Ethics of Krabbe Screening. Public Health Ethics 2013; 6: 114-119
• 75 Ross LF, Waggoner DJ. Parents: critical stakeholders in expanding newborn screening. J Pediatr 2012; 161 (03) 385-389
• 76 Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav 2010; 51 (04) 408-423
• 77 Borry P, Stultiens L, Nys H, Cassiman JJ, Dierickx K. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet 2006; 70 (05) 374-381
• 78 Levy HL. Newborn screening: the genomic challenge. Mol Genet Genomic Med 2014; 2 (02) 81-84